Company research / CRMD

CorMedix Inc. (CRMD)

CIK 0001410098 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, CorMedix Inc. reported revenue of $311.71M. Revenue grew 617.0% from the prior annual period.

Key ratios (year ended 2025-12-31)

88.5%
Gross margin
48.2%
Operating margin
52.3%
Net margin
40.2%
Return on year-end equity
617.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-19

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView